SUBCUTANEOUS (SC) INJECTION

BENLYSTA SC is the first and only subcutaneous option
approved for weekly treatment of SLE

Subcutaneous injection: 200 mg once-weekly

BENLYSTA SC is supplied as:

200 mg/mL single-dose prefilled autoinjector
200 mg/mL single-dose prefilled glass syringe

If transitioning from intravenous therapy with BENLYSTA to subcutaneous administration, administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose. IV and SC are not to be used concurrently.

Building BENLYSTA into patients' weekly routines may help improve adherence.

Administration Instructions
  • It is recommended that the first subcutaneous injection of BENLYSTA should be under the supervision of a healthcare professional. The healthcare provider should provide proper training in subcutaneous technique and education about signs and symptoms of hypersensitivity reactions. A patient may self-inject or the patient caregiver may administer BENLYSTA subcutaneously after the healthcare provider determines it is appropriate.
  • Instruct the patient or patient caregiver to follow the directions for administration provided in the Instructions for Use.
  • Instruct the patient to remove the autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30 minutes prior to the subcutaneous injection. Do not warm BENLYSTA in any other way.
  • Prior to administration, instruct the patient or patient caregiver to visually inspect the window of the autoinjector or the prefilled syringe for particulate matter or discoloration. BENLYSTA should be clear to opalescent and colorless to pale yellow. Do not use BENLYSTA if the product exhibits discoloration or particulate matter. Instruct the patient not to use the BENLYSTA autoinjector or prefilled syringe if dropped on a hard surface.
  • When injecting in the same body region, advise the patient to use a different injection site each week; never give injections into areas where the skin is tender, bruised, red, or hard.
  • Instruct the patient to administer BENLYSTA 200 mg once a week, preferably on the same day each week.
  • If a dose is missed, instruct the patient to administer a dose as soon as the patient remembers. Thereafter, the patient can resume dosing on their usual day of administration or start a new weekly schedule from the day that the missed dose was administered. It is not recommended to administer 2 doses on the same day.

INTRAVENOUS (IV) INFUSION

BENLYSTA IV is administered as a 1-hour infusion

10 mg/kg administered every 2 weeks for the first 3 doses and every 4 weeks thereafter

BENLYSTA IV is supplied as:

120 mg in a 5-mL single-dose vial
400 mg in a 20-mL single-dose vial

If transitioning from intravenous therapy with BENLYSTA to subcutaneous administration, administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose. IV and SC are not to be used concurrently.


Dosing Schedule

Consider scheduling the first 3 doses in advance to start your patients off right.

Useful tools to support your patients
Find the vial combination that helps minimize product waste.
Calculate patients’ infusion dates.
Administration Instructions
  • The diluted solution of BENLYSTA should be administered by intravenous infusion over a period of 1 hour.
  • BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis.
  • BENLYSTA should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of BENLYSTA with other agents.
  • Do not administer as an intravenous push or bolus.
Additional dosing resources for BENLYSTA IV

831319R0 February 2018

Chat